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515
In 2015, 71 million people worldwide 
were living with one of the six major 
genotypes of hepatitis C virus (HCV) 
and 399 000 people died from the 
infection.1 The 2016 World Health Or-
ganization (WHO) guidelines for the 
screening, care and treatment of people 
with chronic hepatitis C virus infection2 
focused on two points. First, WHO 
recommended considering all infected 
adults, that is, 18 years of age or older, for 
treatment, but prioritizing those at high-
est risk of death or disability or those 
at high risk of transmitting the virus. 
Second, WHO recommended treating 
patients with direct-acting antivirals, 
using different regimens depending on 
hepatitis C virus genotype.
Since then, three key developments 
prompted changes in terms of when to 
treat and what treatment to use. First, 
safe and highly effective direct acting 
antiviral regimens that improve the 
balance of benefit-to-harm of treating 
people with little or no hepatic fibrosis 
became the norm for the treatment 
of all patients. Second, several new, 
pan-genotypic direct acting antiviral 
medicines became available, reducing 
the need for genotyping to guide treat-
ment decisions. Third, the price of direct 
acting antivirals has fallen considerably, 
which enabled a more rapid roll-out of 
treatment in low- and middle-income 
countries.3
Ne w  W HO  g u i d e l i ne s  we re 
launched on World Hepatitis Day4 in 
July 2018. These guidelines are intended 
for public health officials to use as the 
basis for developing national hepatitis 
policies, plans and treatment guidelines.
WHO formulated population, in-
tervention, comparator and outcome 
(PICO) questions that addressed when 
to start treatment and what treatment 
to use. These questions were considered 
for adults 18 years of age or older, ado-
lescents 12–17 years of age and children 
younger than 12 years. WHO commis-
sioned systematic reviews, convened 
a guidelines development group in 
September 2017, drafted the guidelines 
and submitted them to peer review and 
ultimately for clearance by the WHO 
Guidelines Review Committee.
The 2018 guidelines offer new rec-
ommendations in the treatment of hepa-
titis C virus. First, WHO recommends 
offering treatment to all adolescents and 
adults diagnosed with chronic hepatitis 
C virus infection, with the exception of 
pregnant women, irrespective of disease 
stage. Second, the guidelines recom-
mend the use of pangenotypic direct 
acting antivirals in adults. This includes 
those who have never been treated with 
direct-acting antivirals and those who 
previously received interferon and/or 
ribavirin. These regimens and the dura-
tion of treatment depend on the pres-
ence or absence of cirrhosis. In adoles-
cents, WHO recommends direct-acting 
antiviral-based regimens that are still 
genotype-dependent. Treatment in ado-
lescents still requires non pangenotypic 
regimens, and ribavirin for treatment 
of genotype 2 and 3. Third, in children 
diagnosed with chronic hepatitis C virus 
infection, WHO recommends defer-
ring treatment until children reach 12 
years of age. None of the recommended 
pangenotypic direct acting antiviral 
regimens for adults are yet approved 
for use in adolescents and children, but 
approval is anticipated in 2019.
The implications of these new WHO 
recommendations for public health are 
threefold. First, treating all persons in-
fected will allow faster progress towards 
hepatitis C virus elimination as a major 
public health threat by 2030.5 Second, 
the use of pangenotypic regimens re-
moves the need for expensive genotyp-
ing before treatment initiation. Third, 
treatment of adolescents means that 
more people could become adults free 
of hepatitis C virus infection. Further 
efforts to increase testing, especially in 
populations most affected by hepatitis 
C, will contribute to identifying those 
infected and in need of treatment.6 Five 
population groups (people who inject 
drugs, people in prisons or other closed 
settings, men who have sex with men, 
sex workers and indigenous popula-
tions) require specific public health 
approaches because of stigma and dis-
crimination, vulnerability and difficul-
ties in accessing services. Treating all 
persons diagnosed with hepatitis C virus 
infection using pangenotypic direct act-
ing antiviral regimens will simplify care 
and facilitate achieving viral hepatitis 
elimination as established in the Global 
health sector strategy on viral hepatitis, 
approved in 2016.5 ■
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